These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1185 related articles for article (PubMed ID: 15641020)

  • 21. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
    O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why chemotherapy can fail?
    Król M; Pawłowski KM; Majchrzak K; Szyszko K; Motyl T
    Pol J Vet Sci; 2010; 13(2):399-406. PubMed ID: 20731201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel targets for therapy in paediatric oncology.
    Estlin EJ
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Jul; 2(2):141-50. PubMed ID: 12476788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug resistance in multiple myeloma: approaches to circumvention.
    Dalton WS; Jove R
    Semin Oncol; 1999 Oct; 26(5 Suppl 13):23-7. PubMed ID: 10528891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.
    El Maalouf G; Le Tourneau C; Batty GN; Faivre S; Raymond E
    Cancer Treat Rev; 2009 Apr; 35(2):167-74. PubMed ID: 19027240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
    Zhang Y; Wang J; Xiang D; Wang D; Xin X
    Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro.
    Andrews P; Zhao X; Allen J; Li F; Chang M
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):203-14. PubMed ID: 17447067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
    Ellis LM; Hicklin DJ
    Clin Cancer Res; 2008 Oct; 14(20):6371-5. PubMed ID: 18927275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding resistance to targeted cancer drugs through loss of function genetic screens.
    Berns K; Bernards R
    Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Avoidance of apoptosis as a mechanism of drug resistance.
    Dive C
    J Intern Med Suppl; 1997; 740():139-45. PubMed ID: 9350196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.
    Farrell NP
    Semin Oncol; 2004 Dec; 31(6 Suppl 14):1-9. PubMed ID: 15726528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding cisplatin resistance using cellular models.
    Stordal B; Davey M
    IUBMB Life; 2007 Nov; 59(11):696-9. PubMed ID: 17885832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents.
    Deisseroth AB; DeVita VT
    Cancer J Sci Am; 1995; 1(1):15-21. PubMed ID: 9166447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A; Mehta K
    Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
    Saldivar JS; Wu X; Follen M; Gershenson D
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure.
    Lippert TH; Ruoff HJ; Volm M
    Arzneimittelforschung; 2008; 58(6):261-4. PubMed ID: 18677966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Research advance on role of tumor microenvironment in mediating acquired drug resistance].
    Ma XL; Xing H; Ma D
    Ai Zheng; 2007 Aug; 26(8):923-6. PubMed ID: 17697561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
    Katsman A; Umezawa K; Bonavida B
    Drug Resist Updat; 2007; 10(1-2):1-12. PubMed ID: 17306602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.